Skip to main content
. 2014 Sep 25;5(20):10170–10179. doi: 10.18632/oncotarget.2526

Figure 4. LuCa cell migration and invasion mediated by CCR9-CCL25.

Figure 4

SCC (NCI-H520) and AC (NCI-H2126) cells were tested for their ability to migrate [A] and invade [B] toward chemotactic gradients of 0 (open bar) or 100 ng/ml (black bar) of CCL25. The cells were pre-treated with anti-human CCR9 antibody (1 μg/ml) (grey bar) during migration and invasion assays. Asterisks indicate significant differences in migration and invasion between untreated and CCL25-treated or anti-CCR9-treated cell lines (** p < 0.01). Data was analyzed using non-parametric two tailed t-test and is presented as mean +/− S.D., n=3.